Altered 5-Hydroxytryptamine Signaling in Patients With Constipation- and Diarrhea-Predominant Irritable Bowel Syndrome
Authors:
- Stephen LockhartSLStephen Lockhart
- Peter J. WhorwellPWPeter J. Whorwell
- Brian KeevilBKBrian Keevil
- Lesley A. HoughtonLHLesley A. Houghton
- 1 January 2006
- journal article
- Published by Elsevier in Gastroenterology
- Vol. 130 (1) , 34-43
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome 1 ☆Gastroenterology, 2004
- The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double blind, randomized, placebo-controlled studyClinical Gastroenterology and Hepatology, 2003
- Gender differences in plasma 5-hydroxytryptamine (5-HT) concentration in diarrhoea predominant irritable bowel syndrome (d-IBS): Influence of the menstrual cycleGastroenterology, 2003
- Adverse Reactions of Selective Serotonin Reuptake InhibitorsDrug Safety, 1999
- Subtypes of constipation predominant irritable bowel syndrome based on rectal perceptionGut, 1998
- Allelic Variation of Human Serotonin Transporter Gene ExpressionJournal of Neurochemistry, 1996
- Anorectal manometric abnormalities and colonic propulsive impairment in patients with severe chronic idiopathic constipationDigestive Diseases and Sciences, 1994
- Intestinal motility in irritable bowel syndrome: Is IBS a motility disorder?Digestive Diseases and Sciences, 1993
- Storage of 5-hydroxytryptamine in human blood plateletsCellular and Molecular Life Sciences, 1972
- The motility of the pelvic colonGut, 1962